Duloxetine Capsule, Delayed Release
Product Images NDC 68180-296

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 68180-296). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lupin Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

C5b0f981 45c3 4e15 B712 984b4a4f6a57 01

Chemical structure of Duloxetine hydrochloride, showing its molecular framework including a naphthyl group, a thiophene ring, and an amine group as part of the structure.*

FDA Label Image

C5b0f981 45c3 4e15 B712 984b4a4f6a57 02

A Kaplan-Meier curve comparing the proportion of patients with relapse over time (days) between two treatments: placebo and Duloxetine. The graph shows relapse proportions on the vertical axis and time from randomization to relapse on the horizontal axis, illustrating a lower relapse proportion in patients treated with Duloxetine compared to placebo over approximately 200 days.*

FDA Label Image

C5b0f981 45c3 4e15 B712 984b4a4f6a57 03

A Kaplan-Meier estimator plot showing the proportion of patients with relapse over time in days from randomization, comparing duloxetine treatment (solid line) with placebo (dashed line). The y-axis represents the proportion of patients with relapse, ranging from 0 to 1, and the x-axis shows time in days up to around 250.*

FDA Label Image

C5b0f981 45c3 4e15 B712 984b4a4f6a57 04

A line graph comparing the percentage of patients improved versus the percent improvement in pain from baseline for duloxetine 60 mg BID, duloxetine 60 mg QD, duloxetine 20 mg QD, and placebo groups. The graph shows higher percentages of patient improvement for duloxetine doses relative to placebo across increasing pain improvement percentages.*

FDA Label Image

C5b0f981 45c3 4e15 B712 984b4a4f6a57 05

A line graph showing the percentage of patients improved on the vertical axis versus percent improvement in pain from baseline on the horizontal axis. The graph compares three groups: Duloxetine 60 mg twice daily (BID), Duloxetine 60 mg once daily (QD), and placebo. The graph illustrates the distribution of pain improvement percentages among patients across these groups.*

FDA Label Image

C5b0f981 45c3 4e15 B712 984b4a4f6a57 06

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo groups. The x-axis represents percent improvement in pain, and the y-axis represents the percentage of patients improved. Duloxetine groups show higher improvement percentages compared to placebo across levels of pain improvement.*

FDA Label Image

C5b0f981 45c3 4e15 B712 984b4a4f6a57 07

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline for duloxetine and placebo. The curves compare Duloxetine 120 mg twice daily, Duloxetine 60 mg once daily (two data series), and placebo, illustrating patient response rates across varying levels of pain improvement.*

FDA Label Image

C5b0f981 45c3 4e15 B712 984b4a4f6a57 08

A line graph comparing the percentage of patients improved at various levels of percent improvement in pain from baseline (BOCF) between placebo and Duloxetine 60/120 mg once daily. The graph shows two curves representing the placebo group and the Duloxetine group, indicating patient improvement percentages along the vertical axis and percent pain improvement along the horizontal axis.*

FDA Label Image

C5b0f981 45c3 4e15 B712 984b4a4f6a57 09

A line graph comparing percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg once daily and placebo. The x-axis shows percent improvement in pain, and the y-axis shows percentage of patients improved, with Duloxetine generally showing higher improvement rates than placebo.*

FDA Label Image

C5b0f981 45c3 4e15 B712 984b4a4f6a57 10

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (Bocf) for Duloxetine 60/120 mg once daily and placebo. The x-axis represents percent pain improvement ranging from >0 to 100, and the y-axis shows the percentage of patients improved from 0 to 100. Duloxetine shows higher patient improvement percentages across pain improvement levels compared to placebo.*

FDA Label Image

C5b0f981 45c3 4e15 B712 984b4a4f6a57 11

Label for Duloxetine Delayed-release Capsules USP, 20 mg strength, in a package containing 30 capsules. The product is manufactured by Lupin Limited, Goa, India, and labeled for Lupin Pharmaceuticals, Inc. The label includes dosage instructions, storage conditions, a barcode, and a QR code linking to the medication guide.*

FDA Label Image

C5b0f981 45c3 4e15 B712 984b4a4f6a57 12

Label for Duloxetine 30 mg delayed-release capsules USP, containing 30 capsules per package. Manufactured by Lupin Limited, Goa, India, and marketed by Lupin Pharmaceuticals, Inc. The label includes dosage information, storage instructions, a barcode, and a QR code linking to the medication guide.*

FDA Label Image

C5b0f981 45c3 4e15 B712 984b4a4f6a57 13

Label for Duloxetine Delayed-release Capsules USP 40 mg by Lupin Pharmaceuticals, Inc. The label includes the NDC 68180-297-06 and states the package contains 30 capsules. It provides storage instructions, dosage information, and a QR code linking to the medication guide. The product is manufactured by Lupin Limited in India and for Lupin Pharmaceuticals, Inc. in the United States.*

FDA Label Image

C5b0f981 45c3 4e15 B712 984b4a4f6a57 14

Label for Duloxetine 60 mg delayed-release capsules, USP, manufactured and distributed by Lupin Pharmaceuticals, Inc. The label displays the drug name, strength, dosage form, quantity (30 capsules), and includes storage instructions and manufacturing information from Lupin Limited, India. The packaging includes a barcode and a capsule image with color segments marked 'LU' and 'Q03'.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.